Financial
Listed (HOLX); FY2025 full-year figures not yet captured, so not assessed.
Agreed in Oct 2025 to be acquired by Blackstone and TPG funds (up to $79 a share).
Hologic
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedListed: HOLX
Listed (HOLX); FY2025 full-year figures not yet captured, so not assessed.
Agreed in Oct 2025 to be acquired by Blackstone and TPG funds (up to $79 a share).
Source: official results release · Year ended 2025-09-27 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | — | — | — | — | Hologic |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Apr 2026: Blackstone and TPG completed their take-private of Hologic for up to $79 per share; Joe Almeida replaced Stephen MacMillan as CEO. Jul 2026: a class action filed in Massachusetts alleges personal data was exposed in a cyberattack on Hologic.
Cyber & information governance
Jul 2026: a class action lawsuit alleges sensitive personal data held by Hologic was exposed in a ransomware attack; HSH did not find a company confirmation of the incident in its search. NHS DSPT status not yet checked.
Regulatory & clinical safety
Jul 2026: FDA updated the BioZorb breast marker recall, citing 252 reported injuries and no deaths; Hologic stopped shipping the markers in 2024. Dec 2024: an FDA warning letter cited design control, CAPA and adverse-event reporting failures for BioZorb.
Contract performance
No notable troubled implementations, terminations, customer disputes or significant new NHS contracts involving Hologic found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.